Growth and Functional Reactivity of Lymphocytes Obtained from Three Anatomic Compartments in Patients with Non-Small-Cell Lung Cancer (NSCLC)

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 5, 2003, Pages 735-749

  Yannelli, John R ^a,b   Hirscowitz, Edward ^a   Wroblewski, Joanne M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cytotoxic T lymphocyte (CTL); Immunotherapy; Non small cell lung cancer (NSCLC)

Indexed keywords

B7 ANTIGEN; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A30 ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CANCER IMMUNOTHERAPY; CELL GROWTH; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LUNG NON SMALL CELL CANCER; PLEURA FLUID; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

EID: 0242581519     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803770418283     Document Type: Article

References (66)

1. Schiller JH. Lung cancer: therapeutic modalities and cytoprotection. Lung 1998;176:145.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5.
3. Medley L, Cullen M. Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer. Curr Opin Oncol 2002;14:384.
4. Smythe WR. Treatment of stage I and II non-small-cell lung cancer. Cancer Control 2001;8:318.
5. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380.
6. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001;250:462.
7. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response. J Natl Cancer Inst 1991;83:932.
8. Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475.
9. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159.
10. Pockaj BA, Sherry RM, Wei JP, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731.
11. Takenoyama M, Yoshino L, Fujie H, et al. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: Implications of the shared antigens expressed in HLA-A24 lung cancer cells. Jpn J Cancer Res 1998;89:60.
12. Yoshino I, Takenoyama M, Fujie H, et al. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer. Jpn J Cancer Res 1997;88:743.
13. Seki N, Hoshino T, Kikuchi M, et al. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Cell Immunol 1997;175:101.
14. Echchakir H, Vergnon I, Dorothee G, et al. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol 2001;12:537.
15. Hanagiri T, Yoshino L, Takenoyama M, et al. Effects of interleukin-12 on the induction of cytotoxic T lymphocytes from the regional lymph node lymphocytes of patients with lung adenocarcinoma. Jpn J Cancer Res 1998;89:192.
16. Bixby DL, Yannelli JR. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 1998;78:685.
17. Takenoyama M, Yoshino I, Eifuku R, et al. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res 2001;92:309.
18. So T, Takenoyama M, Sugaya M, et al. Generation of autologous tumor-specific T cell clones from a patient with adenosquamous carcinoma of the lung. Jpn J Clin Oncol 2001;31:311.
19. Weynants P, Thonnard J, Marchand M, et al. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med 1999;159:55.
20. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3.
21. Yoshino I, Goedegebuure PS, Peoples GE, et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387.
22. Karanikas V, Colau D, Baurain JF, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001;61:3718.
23. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277.
24. Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999;59:4056.
25. Nakao M, Shichijo S, Imaizumi T, et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000;164:2565.
26. Yamada A, Kawano K, Koga M, et al. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001;61:6459.
27. Gomi S, Nakao M, Niiya F, et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999;163:4994.
28. Kawano K, Gomi S, Tanaka K, et al. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res 2000;60:3550.
29. Nishizaka S, Gomi S, Harada K, et al. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res 2000;60:4830.
30. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996;78:244.
31. Melioli G, Ratto GB, Ponte M, et al. Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Immunother 1996;19:224.
32. Kradin RL, Kumick JT, Lazarus DS, et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;1:577.
33. Yano T, Ishida T, Yoshino I, et al. A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects. Biotherapy 1991;3:245.
34. Semino C, Martini L, Queirolo P, et al. Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience. Anticancer Res 1999;19:5645.
35. Melioli G, Ratto G, Guastella M, et al. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: Functional and molecular characterisation for their use in adoptive immunotherapy. Eur J Cancer 1994;30A:97.
36. Kradin RL, Boyle LA, Preffer FI, et al. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987;24:76.
37. Yannelli JR, Hyatt C, McConnell S, et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer 1996;65:413.
38. Yannelli JR, Crumpacker DB, Good RW, et al. Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy. J Immunol Methods 1990;130:91.
39. Gazdar AF, Oie HK. Cell culture methods for human lung cancer. Cancer Genet Cytogenet 1986;19:5.
40. Oie HK, Russell EK, Carney DN, Gazdar AF. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl 1996;24:24.
41. Wroblewski JM, Bixby DL, Borowski C, Yannelli JR. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer 2001;33:181.
42. Yannelli JR, Hyatt C, Johnson S, et al. Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-α) or interleukin-2 (IL-2). J Immunol Methods 1993;161:77.
43. Wroblewski JM, Copple A, Batson LP, et al. Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods 2002;264:19.
44. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;5594:850.
45. Kradin R, Kurnick J, Gifford J, et al. Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes. J Clin Immunol 1989;9:378.
46. Ratto GB, Melioli G, Zino P, et al. Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study. J Thorac Cardiovasc Surg 1995;109:1212.
47. Wei YQ, Hang ZB. In situ observation of lymphocyte-tumor cell interaction in human lung carcinoma. Immunol Invest 1989;18:1095.
48. McKneally MF, Maver C, Kausel HW. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet 1976;1:377.
49. Dubinett SM, Kradin RL. Cytokine immunotherapy of non-small cell lung cancer. Reg Immunol 1993;5:232.
50. Jansen RL, Slingerland R, Goey SH, et al. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother 1992;12:70.
51. Bernstein ZP, Goldrosen MH, Vaickus L, et al. Interleukin-2 with ex vivo activated killer cells: Therapy of advanced non-small-cell lung cancer. J Immunother 1991;10:383.
52. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889.
53. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898.
54. Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 1995;13:31.
55. Forsberg G, Ohlsson L, Brodin T, et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 2001;85:129.
56. O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000;83:853.
57. Vose BM, Vanky F, Fopp M, Klein E. Restricted autologous lymphocytotoxicity in lung neoplasia. Br J Cancer 1978;38:375.
58. Vose BM, Bonnard GD. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2. Int J Cancer 1982;29:33.
59. Vose BM, Bonnard GD. Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells. Nature 1982;296:359.
60. Slingluff CL Jr, Cox AL, Stover JM Jr, et al. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: Epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994;54:2731.
61. Nakao M, Yamana H, Imai Y, et al. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995;55:4248.
62. Yannelli JR, McConnell S, Parker L, et al. Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: Comparison of functional reactivity and melanoma antigen recognition. J Immunother 1995;18:263.
63. Stevens EJ, Jacknin L, Robbins PF, et al. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J Immunol 1995;154:762.
64. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993;25:338.
65. Swisher SG, Kiertscher SM, Golub SH, et al. Pulmonary macrophages suppress the proliferation and cytotoxicity of tumor-infiltrating lymphocytes. Am J Respir Cell Mol Biol 1993;8:486.
66. Yoshino I, Yano T, Miyamoto M, et al. Characterization of lung squamous cell carcinoma-derived T-cell suppressive factor. Cancer 1993;72:2347.